We are live on
!
Find out more
Ultragenyx Pharmaceutical
RARE
RARE
295 hedge funds and large institutions have $2.05B invested in Ultragenyx Pharmaceutical in 2026 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 125 increasing their positions, 83 reducing their positions, and 48 closing their positions.
New
Increased
Maintained
Reduced
Closed
200% more funds holding in top 10
Funds holding in top 10: 2 → 6 (+4)
51% more repeat investments, than reductions
Existing positions increased: 125 | Existing positions reduced: 83
29% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 48
4.16% more ownership
Funds ownership: 97.37% → 101.53% (+4.2%)
3% more funds holding
Funds holding: 287 → 295 (+8)
8% more call options, than puts
Call options by funds: $27.9M | Put options by funds: $25.8M
5% less capital invested
Capital invested by funds: $2.16B → $2.05B (-$108M)
Holders
295
Holders Change
+8
Holders Change %
+2.79%
% of All Funds
3.63%
Holding in Top 10
6
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+200%
% of All Funds
0.07%
New
62
Increased
125
Reduced
83
Closed
48
Calls
$27.9M
Puts
$25.8M
Net Calls
+$2.02M
Net Calls Change
-$26.3M
Top Buyers
Top Sellers
| 1 |
JP Morgan Chase
New York
|
-$84M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$63.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$53.6M |
| 4 |
SCM
Suvretta Capital Management
New York
|
-$46.4M |
| 5 |
BNP Paribas Asset Management
Paris,
France
|
-$33.4M |